Key result
Biochemical mechanisms of myocardial contractility involve cyclic AMP-mediated membrane phosphorylation for short-term augmentation and rapid replacement of contractile proteins in hypertrophy.
Answers are grounded in this paper and cite their sources.
This review highlights the biochemical mechanisms underlying myocardial contractility and the changes in contractile proteins during cardiac hypertrophy and failure.
NEW information regarding the chemical basis for adjustments in cardiac performance has recently come to light. Short-term augmentation of contractility may be mediated by cyclic AMP through a mechanism that involves membrane phosphorylation. In addition, studies of biochemical changes that occur in cardiac hypertrophy indicate that contractile proteins are rapidly replaced in response to work overload. It has also been suggested that an abnormal myosin species underlies the defective performance of hypertrophied and failing hearts; no structural abnormality in myosin or other contractile proteins has been identified, however. Before the evidence of multiple biochemical defects in these hearts is discussed, . . .
No takes yet. Share an insight, caveat, or question.
Bleich et al. (1974) conducted a review in Cardiac hypertrophy and heart failure. Biochemical mechanisms of myocardial contractility involve cyclic AMP-mediated membrane phosphorylation for short-term augmentation and rapid replacement of contractile proteins in hypertrophy.
Synapse has enriched 10 related papers. Consider them for comparative context: